Cytokinetics, Incorporated (CYTK) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in South San Francisco, CA, United States. Der aktuelle CEO ist Robert I. Blum.
CYTK hat IPO-Datum 2004-04-30, 498 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $8.17B.
Cytokinetics, Incorporated is a late-stage biopharmaceutical company dedicated to discovering, developing, and commercializing small molecule drugs that modulate muscle function and contractility to treat debilitating diseases. The company's pipeline includes omecamtiv mecarbil, a cardiac myosin activator in Phase III trials for heart failure, and reldesemtiv, a skeletal muscle troponin activator in Phase III development for amyotrophic lateral sclerosis and spinal muscular atrophy. Additional candidates in development include aficamten, a cardiac myosin inhibitor in Phase III trials for obstructive hypertrophic cardiomyopathy, alongside earlier-stage programs such as CK-136 and CK-3772271. Founded in 1997 and headquartered in South San Francisco, California, Cytokinetics maintains a strategic alliance with Astellas Pharma Inc. to advance its muscle-focused therapeutic platform.
